CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with ...

A Zevra Therapeutics drug is now the first FDA-approved therapy for an ultra-rare, inherited metabolic disorder whose effects on the central nervous system can become fatal by the time a patient is a ...

Molecular profiling of over 1,000 nasopharyngeal cancer (NPC) patients’ tumours reveals distinct differences in tumour microenvironment of locoregionally advanced NPC, supporting the use of ...

GeneDx Holdings Corp. (NASDAQ:WGS) is one of the most promising stocks under $100 to buy. On March 10, GeneDx and Zevra Therapeutics (NASDAQ:ZVRA) announced a new partnership to launch a sponsored ...

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving ...

In March 2026, GeneDx Holdings Corp. announced a Niemann-Pick disease type C sponsored genetic testing program with Zevra Therapeutics, expanding access to ExomeDx at no cost for eligible U.S.